Choices, Choices

At Motley Fool, Brian Orelli sizes up both Pacific Biosciences and Complete Genomics to determine which one is the "better buy." Orelli notes that some analysts are skeptical about sequencing's prospects, though he isn't since there is a demand for sequencing and because "the bust [is] still many years away." As for choosing between the two companies, Orelli says, "It's too early to make a definitive call, but of the two, I like PacBio better because I'

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.